-
公开(公告)号:US20050250761A1
公开(公告)日:2005-11-10
申请号:US11122345
申请日:2005-05-05
申请人: Stephen Fakhoury , Helen Lee , Jessica Reed , Kevin Schlosser , Karen Sexton , Haile Tecle , Roy Winters
发明人: Stephen Fakhoury , Helen Lee , Jessica Reed , Kevin Schlosser , Karen Sexton , Haile Tecle , Roy Winters
IPC分类号: A61K31/517 , A61K31/5377 , A61K31/55 , C07D239/94 , C07D401/12 , C07D413/02 , C07D43/02
CPC分类号: C07D239/94 , C07D401/12 , C07D403/12
摘要: This invention provides quinazoline compounds of the formula: wherein: R1 is halo; R2 is H or halo; R3 is a) C1-C3 alkyl, optionally substituted by halo; or b) —(CH2)n-morpholino, —(CH2)n-piperidine, —(CH2)n-piperazine, —(CH2)n—-piperazine-N(C1-C3 alkyl), —(CH2)n-pyrrolidine, or —(CH2)n-imidazole; n is 1 to 4; R4 is —(CH2)m-Het; Het is morpholine, piperidine, piperazine, piperazine-N(C1-C3 alkyl), imidazole, pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each optionally substituted by alkyl, halo, OH, NH2, NH(C1-C3 alkyl) or N (C1-C3 alkyl)2; m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof, as well as processes and intermediate compounds for making them, useful pharmaceutical compositions and methods of using the compounds in the treatment of proliferative diseases.
摘要翻译: 本发明提供下式的喹唑啉化合物:其中:R 1是卤素; R 2是H或卤素; R 3是a)任选被卤素取代的C 1 -C 3 - 烷基; 或b) - (CH 2)n - 吗啉代, - (CH 2)n - 哌啶, - (CH 2)n - 哌嗪, - (CH 2)n - 哌嗪-N(C < 或 - (CH 2)n - 吡咯烷,或 - (CH 2)n - 2 N) - 咪唑; n为1〜4; R 4是 - (CH 2 CH 2)m -Het; Het是吗啉,哌啶,哌嗪,哌嗪-N(C 1 -C 3烷基),咪唑,吡咯烷,氮杂环庚烷,3,4-二氢-2H-吡啶, 或3,6-二氢-2H-吡啶,各自任选被烷基,卤素,OH,NH 2,NH(C 1 -C 3) (C 1 -C 6烷基)或N(C 1 -C 3烷基)2。 m为1-3; X为O,S或NH; 或其药学上可接受的盐,以及制备它们的方法和中间体化合物,有用的药物组合物和使用该化合物治疗增殖性疾病的方法。
-
公开(公告)号:US20050059710A1
公开(公告)日:2005-03-17
申请号:US10896514
申请日:2004-07-22
申请人: Stephen Barrett , Michael Kaufman , Mark Plummer , Jessica Reed , Bruce Roth , Kevin Schlosser
发明人: Stephen Barrett , Michael Kaufman , Mark Plummer , Jessica Reed , Bruce Roth , Kevin Schlosser
IPC分类号: A61P17/06 , A61P29/00 , A61P35/00 , A61P37/00 , C07D213/50 , C07D233/54 , C07D233/64 , C07D263/32 , C07D277/24 , C07D277/28 , C07D213/46 , A61K31/135 , A61K31/277 , A61K31/401 , A61K31/44
CPC分类号: C07D277/24 , C07C225/22 , C07D213/50 , C07D233/64 , C07D263/32
摘要: The present invention relates to diphenylamino ketone derivatives, pharmaceutical compositions and methods of use thereof.
摘要翻译: 本发明涉及二苯基氨基酮衍生物,药物组合物及其使用方法。
-
公开(公告)号:US20050004186A1
公开(公告)日:2005-01-06
申请号:US10725206
申请日:2003-12-01
申请人: Stephen Barrett , Cathlin Flamme , Michael Kaufman , Mark Plummer , Jessica Reed , Joseph Warmus , Lu-Yan Zhang
发明人: Stephen Barrett , Cathlin Flamme , Michael Kaufman , Mark Plummer , Jessica Reed , Joseph Warmus , Lu-Yan Zhang
IPC分类号: A61P29/00 , A61P35/00 , C07D249/08 , C07D249/14 , C07D271/10 , C07D271/113 , C07D285/12 , C07D285/135 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/14 , C07D285/14 , A61K31/4196 , A61K31/4245 , A61K31/433 , C07D271/12
CPC分类号: C07D249/08 , C07D271/10 , C07D271/113 , C07D285/135 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/14
摘要: This invention provides substituted Phenyl-(2-[1,3,4]thiadiazol-2-yl-phenyl)-amine and (2-[1,3,4]Oxadiazol-2-yl-phenyl)phenyl-amine compounds which act as inhibitors of MAPK/ERK Kinase (“MEK”) enzymes and pharmaceutical compositions and methods for their use in immunomodulation and in the treatment and alleviation of inflammation, and proliferative diseases such as cancer and restenosis.
摘要翻译: 本发明提供了取代的苯基 - (2- [1,3,4]噻二唑-2-基 - 苯基) - 胺和(2- [1,3,4]恶二唑-2-基 - 苯基)苯基 - 胺化合物,其中 作为MAPK / ERK激酶(“MEK”)酶的抑制剂及其用于免疫调节和治疗和减轻炎症以及增殖性疾病如癌症和再狭窄的药物组合物和方法。
-
公开(公告)号:US20110206578A1
公开(公告)日:2011-08-25
申请号:US13033206
申请日:2011-02-23
申请人: Evan Foster , Jessica Reed , Heather Shepherd , Christina Inman , Scott Benson
发明人: Evan Foster , Jessica Reed , Heather Shepherd , Christina Inman , Scott Benson
CPC分类号: C12Q1/6834 , B01J19/0046 , B01J2219/00612 , B01J2219/00635 , B01J2219/00637 , B01J2219/00648 , B01J2219/00722 , B01L3/502707
摘要: Methods for activating and/or reactivating a metal oxide surface for deposition, immobilizing, and/or growing a biological sample (e.g., an oligonucleotide, a polynucleotide, functionalized particle, a polymer, etc.) thereon are disclosed. The metal oxide surface (e.g., zirconium oxide) can be activated and/or reactivated by exposing the metal oxide surface to various activation and/or treatment protocols capable of enhancing a slide's activity relative to the activity of an untreated slide. The activation and/or treatment protocol can include subjecting the slide (or at least the metal oxide layer) to an oxygen plasma treatment and/or a peroxide solution for an amount of time sufficient to activate and/or reactivate the metal oxide surface. Activated sequencing slides capable of incorporation, for example, into various embodiments of a flow cell for use in NGS platforms are also disclosed herein.
摘要翻译: 公开了用于活化和/或重新激活用于在其上沉积,固定和/或生长生物样品(例如寡核苷酸,多核苷酸,官能化颗粒,聚合物等)的金属氧化物表面的方法。 金属氧化物表面(例如,氧化锆)可以通过将金属氧化物表面暴露于能够相对于未处理载玻片的活性增强载玻片的活性的各种活化和/或处理方案而被活化和/或再活化。 活化和/或处理方案可以包括使载玻片(或至少金属氧化物层)经历氧等离子体处理和/或过氧化物溶液足以活化和/或重新活化金属氧化物表面的时间量。 本文还公开了能够并入例如用于NGS平台的流动池的各种实施方案中的活化测序载玻片。
-
-
-